<DOC>
	<DOCNO>NCT00633724</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immune response clinical response different dose HLA-A*2402 restrict epitope peptide URLC10 , TTK , VEGFR1 VEGFR2 emulsify Montanide ISA 51 .</brief_summary>
	<brief_title>Multiple-Vaccine Therapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>URLC10 TTK identify cancer specific molecule especially non small cell lung cancer use genome-wide expression profile analysis cDNA microarray technique . We determine HLA-A*2402 restrict epitope peptide derive molecule . We also tend use peptide target tumor angiogenesis . VEGF receptor 1 2 essential target tumor angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Disease characteristic 1 . Advanced recurrent non small cell lung cancer 2 . Second line later therapeutic status Patient characteristic 1 . ECOG performance status 02 2 . Life expectancy &gt; 3 month 3 . HLAA*2402 4 . Laboratory value follow 1500/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 75000/mm3 Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 99IU/L Alanine transaminase &lt; 126IU/L Creatinine &lt; 2.2mg/dl 5 . Able willing give valid write informed consent 1 . Active uncontrolled cardiac disease ( include patient myocardial infarction within 6 month entry ) 2 . Pregnancy ( woman child bear potential ) 3 . Active uncontrolled infectious disease 4 . Adrenal cortical steroid hormone dependent status 5 . Decision unsuitableness principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>